A 24-Week Randomized Multicenter Trial to Evaluate the Efficacy and Safety of ZD4522 10 to 40 mg and Extended-release Niacin 0.5 to 2g Monotherapy, as well as Selected Combinations of ZD4522 and Extended-release Niacin, in the Treatment of Subjects with Type IIb or IV Hyperlipidemia

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.